Search results
Results from the WOW.Com Content Network
Pages in category "Drugs developed by Novartis" The following 135 pages are in this category, out of 135 total. This list may not reflect recent changes. A.
E. W. Kemble's "Death's Laboratory" on the cover of Collier's (June 3, 1905). A patent medicine, also known as a proprietary medicine or a nostrum (from the Latin nostrum remedium, or "our remedy") is a commercial product advertised to consumers as an over-the-counter medicine, generally for a variety of ailments, without regard to its actual effectiveness or the potential for harmful side ...
Novartis also initiated a program to assist patients who could not afford its version of the drug, concurrent with its product launch. [175] When examination of Novartis' patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling Gleevec in India and by advocacy ...
Novartis has been These teams are spending big money bulking up pipelines with specialty drugs designed to replace prior generation therapies. Novartis' Plans to Protect Sandostatin's Billion ...
Swiss drug company Novartis AG (NVS) dove into the recent wave of pharma dealmaking today. The industry has been in consolidation mode as many drugs are due to come off patent in recent years, as ...
Swiss drug major Novartis AG (NYSE: NVS) plans to petition the U.S. Supreme Court to uphold the validity of the Gilenya (fingolimod) dosing regimen patent. The decision comes as the U.S. Court of ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
(Reuters) -The U.S. Food and Drug Administration has approved the use of Novartis' drug to reduce excess protein in the urine of patients with a type of kidney disease, the health regulator's ...